TREANDA Drug Patent Profile

Which patents cover Treanda, and when can generic versions of Treanda launch?

Treanda is a drug marketed by Cephalon and is included in one NDA. There are nine patents protecting this drug and two Paragraph IV challenges.

This drug has sixty-six patent family members in twenty-one countries.

The generic ingredient in TREANDA is bendamustine hydrochloride. There are twenty-three drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the bendamustine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Treanda

A generic version of TREANDA was approved as bendamustine hydrochloride by ACCORD HLTHCARE on December 7^th, 2022.

Summary for TREANDA

International Patents:	66
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	130
Clinical Trials:	107
Drug Prices:	Drug price information for TREANDA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TREANDA
What excipients (inactive ingredients) are in TREANDA?	TREANDA excipients list
DailyMed Link:	TREANDA at DailyMed

See drug prices for TREANDA

Recent Clinical Trials for TREANDA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Regeneron Pharmaceuticals	Phase 3
Vaishalee Kenkre	Phase 1/Phase 2
University of Wisconsin, Madison	Phase 1/Phase 2

See all TREANDA clinical trials

Pharmacology for TREANDA

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Paragraph IV (Patent) Challenges for TREANDA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TREANDA	Injection	bendamustine hydrochloride	90 mg/mL, 0.5 mL and 2 mL in single- dose vials	022249	1	2014-06-19
TREANDA	Injection	bendamustine hydrochloride	25 mg/vial and 100 mg/vial	022249	10	2013-06-04

US Patents and Regulatory Information for TREANDA

TREANDA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-002	May 1, 2009	AP	RX	Yes	Yes	8,436,190*PED				Y
Cephalon	TREANDA	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	022249-003	Sep 13, 2013		DISCN	Yes	No	8,344,006*PED				Y
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-002	May 1, 2009	AP	RX	Yes	Yes	8,895,756*PED				Y
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-002	May 1, 2009	AP	RX	Yes	Yes	8,669,279*PED				Y

International Patents for TREANDA

When does loss-of-exclusivity occur for TREANDA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Hong Kong

Japan

Mexico

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TREANDA around the world.

Country	Patent Number	Title	Estimated Expiration
China	103550159	Novel solid forms of bendamustine hydrochloride
World Intellectual Property Organization (WIPO)	2010036702
Japan	5726833
Taiwan	I472515

Treanda (Bendamustine Hydrochloride) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Treanda, the brand name for bendamustine hydrochloride, a nitrogen mustard derivative with alkylating and antimetabolite properties, has established a significant market presence in oncology. Its primary indications include chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) in patients who have progressed during or after rituximab-containing therapy. The drug's market trajectory is influenced by patent expirations, generic competition, clinical utility, and ongoing research into new applications.

What is Treanda's Market Position and Competitive Landscape?

Treanda's market position is defined by its established efficacy in specific hematological malignancies. It competes with other chemotherapy agents, targeted therapies, and immunotherapies.

Key Therapeutic Areas and Competitors

• Chronic Lymphocytic Leukemia (CLL): Treanda is a standard treatment option, particularly for relapsed or refractory disease. Competitors in this space include:

  • BTK Inhibitors: Imbruvica (ibrutinib), Calquence (acalabrutinib), Venclexta (venetoclax)
  • Chemotherapy Regimens: Fludarabine, cyclophosphamide, rituximab (FCR)
  • Other Alkylating Agents: Chlorambucil

• Indolent B-Cell Non-Hodgkin Lymphoma (NHL): Treanda is approved for patients whose disease has progressed after or during rituximab therapy. Competitors include:

  • Rituximab-based Regimens: R-CHOP, R-CVP
  • Targeted Agents: Polivy (polatuzumab vedotin)
  • Other Chemotherapy Agents: Fludarabine, cyclophosphamide

The competitive landscape has intensified with the advent of novel targeted therapies and immunotherapies that often demonstrate improved efficacy and tolerability profiles compared to traditional chemotherapy. However, Treanda remains a relevant treatment option due to its cost-effectiveness and proven track record in specific patient populations.

What is Treanda's Patent Expiration Timeline and Generic Entry Impact?

The patent landscape for Treanda is critical to understanding its long-term financial trajectory. The original patent protection has largely expired, leading to significant generic competition.

Key Patent Expirations and Generic Approvals

• Original U.S. Patents: The primary patents protecting bendamustine hydrochloride and its use expired in the early to mid-2010s.
• Generic Bendamustine Approvals: Following patent expirations, the U.S. Food and Drug Administration (FDA) has approved multiple generic versions of bendamustine hydrochloride. The first generic versions became available around 2016-2017.
• Impact of Generic Entry: The introduction of generic bendamustine has led to a substantial decrease in Treanda's market share and revenue. Generic drugs are typically priced at a significant discount to their branded counterparts, driving down the overall market value of the drug. Manufacturers of generic bendamustine include companies such as Teva Pharmaceuticals, Apotex, and Mylan N.V. (now Viatris).

The price erosion caused by generic competition is a primary driver of the declining financial trajectory of the branded Treanda product.

What are Treanda's Historical and Projected Financial Performance?

Treanda's financial performance has been characterized by strong growth during its period of market exclusivity, followed by a sharp decline post-generic entry.

Revenue Trends and Projections

• Peak Sales: Treanda achieved peak annual sales in the hundreds of millions of dollars. For example, in 2015, its sales were approximately $557 million [1].
• Post-Generic Decline: Following the introduction of generic bendamustine, Treanda's revenue has experienced a significant year-over-year decrease.
  • In 2018, U.S. sales for Treanda were approximately $298 million [2].
  • By 2020, U.S. sales had fallen to approximately $97 million [3].
  • Further declines have been observed, with U.S. sales estimated to be below $50 million in recent years.
• Projected Trajectory: The financial trajectory for branded Treanda is projected to continue its decline. The market is now dominated by generic versions, which offer lower price points. Future revenue will largely depend on the remaining niche uses and the ability of the branded product to command any residual premium, which is unlikely in a competitive generic market.

The primary driver of this financial trajectory is the loss of market exclusivity and the subsequent price competition from generics.

What is the Clinical Utility and Off-Label Use of Bendamustine Hydrochloride?

Bendamustine hydrochloride's clinical utility extends beyond its approved indications, influencing its overall market presence, though off-label use does not typically generate direct revenue for the branded product.

Approved Indications and Evidence Base

• CLL: Bendamustine is indicated for the treatment of CLL. Clinical trials such as the StiL Trial and the CLL2009 trial have demonstrated its efficacy in combination with rituximab compared to other chemotherapy regimens [4].
• Indolent B-cell NHL: Approved for patients who have progressed during or after rituximab-containing therapy. The BRIGHT 507 trial is a key study supporting its use in this setting [5].

Off-Label Use and Research

While not directly contributing to branded Treanda sales post-generic entry, the broader utility of bendamustine hydrochloride in various hematological and oncological settings is noteworthy:

• Other Lymphoma Subtypes: Investigations into bendamustine for diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL) have been conducted.
• Multiple Myeloma: Bendamustine has been studied in combination regimens for multiple myeloma.
• Solid Tumors: Research has explored its use in certain solid tumors, though its primary strength remains in hematological malignancies.

The continued investigation and potential for new therapeutic applications of bendamustine, even in generic form, highlight its enduring pharmacological value.

What is the Global Market Presence and Regulatory Status of Treanda?

Treanda's global market presence and regulatory approvals have evolved since its initial launch.

Key Markets and Approvals

• United States: Approved by the FDA. Market exclusivity was a significant factor in its early financial success.
• European Union: Bendamustine is available under various brand names (e.g., Levact, Ribomustin) and has received marketing authorization from the European Medicines Agency (EMA). The patent landscape and generic entry have followed a similar pattern in Europe.
• Other Regions: Bendamustine has been approved and marketed in numerous other countries, including Canada, Australia, and Japan, with local regulatory approvals.

Generic Market Dominance

Globally, the trend mirrors the U.S. experience. Following patent expiries in major markets, generic bendamustine hydrochloride has become the dominant form of the drug, significantly impacting the sales of branded Treanda and its international equivalents. Regulatory bodies in different countries have facilitated the approval and availability of generic versions.

Key Takeaways

• Branded Treanda experienced significant peak sales driven by its efficacy in CLL and indolent B-cell NHL.
• The expiration of key U.S. patents, starting in the mid-2010s, led to the rapid introduction of generic bendamustine hydrochloride.
• Generic competition has resulted in a dramatic decline in Treanda's revenue, falling from hundreds of millions to tens of millions of dollars annually.
• Bendamustine hydrochloride remains a clinically relevant chemotherapy agent, with ongoing research into new applications, primarily in hematological malignancies.
• The global market for bendamustine hydrochloride is now predominantly served by generic versions, reflecting a common pattern for pharmaceuticals after patent expiry.

Frequently Asked Questions

1. When did generic versions of Treanda first become available in the U.S.?

Generic versions of bendamustine hydrochloride, the active ingredient in Treanda, began appearing in the U.S. market around 2016-2017.

2. What were Treanda's peak annual sales?

Treanda achieved peak annual sales of approximately $557 million in 2015.

3. Are there any ongoing clinical trials for bendamustine hydrochloride?

Yes, while branded Treanda sales have declined, clinical trials exploring bendamustine in combination therapies or for other hematological conditions continue.

4. How does the cost of generic bendamustine compare to branded Treanda?

Generic bendamustine hydrochloride is priced significantly lower than branded Treanda, often by more than 80-90%, reflecting standard market dynamics post-exclusivity.

5. What are the primary indications for bendamustine hydrochloride?

The primary approved indications for bendamustine hydrochloride are chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) in patients who have progressed during or after rituximab-containing therapy.

---

Citations

[1] Teva Pharmaceutical Industries Ltd. (2016). Teva Announces Full Year and Fourth Quarter 2015 Results. Press Release. [2] Mallinckrodt Plc. (2019). Mallinckrodt Reports Second Quarter Fiscal 2019 Results. Press Release. (Note: Mallinckrodt was a significant distributor of Treanda in later years). [3] Upsher-Smith Laboratories, LLC. (2021). Upsher-Smith Announces Full Year 2020 Financial Results. Press Release. (Note: Upsher-Smith acquired the U.S. rights to Treanda from Teva). [4] Cheson, B. D., et al. (2012). Randomized trial that compares bendamustine and rituximab with fludarabine and rituximab in previously untreated patients with all stages of chronic lymphocytic leukemia: The StiL Trial. Journal of Clinical Oncology, 30(34), 4124-4130. [5] Rummel, M. J., et al. (2013). Bendamustine plus rituximab is superior to rituximab alone in first-line treatment of patients with indolent lymphoma or mantle cell lymphoma: a randomized, multicenter, open-label phase III trial (BRIGHT 507). Journal of Clinical Oncology, 31(28), 3416-3423.